07:00 EDT Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $53.00 per share in cash
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- M&A News: Soleno Therapeutics Stock (SLNO) Surges 28% as Neurocrine Biosciences Lines up $2.5B Deal
- Neurocrine appoints Andrew Ratz as Chief Technical Operations Officer
- Neurocrine price target raised to $177 from $176 at JPMorgan
- Neurocrine initiated with an Outperform at Wolfe Research
- Neurocrine price target lowered to $140 from $169 at Truist